Equities analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings per share (EPS) of ($0.14) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.08). Galectin Therapeutics posted earnings of ($0.12) per share during the same quarter last year, which indicates a negative year over year growth rate of 16.7%. The firm is scheduled to announce its next quarterly earnings report on Friday, May 10th.
On average, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.58) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.42). For the next financial year, analysts anticipate that the business will report earnings of ($0.55) per share, with EPS estimates ranging from ($0.58) to ($0.52). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08).
In other news, Director Gilbert F. Amelio sold 30,000 shares of Galectin Therapeutics stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $5.00, for a total transaction of $150,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richard E. Uihlein bought 51,500 shares of the firm’s stock in a transaction dated Tuesday, January 29th. The shares were acquired at an average price of $4.87 per share, for a total transaction of $250,805.00. Following the completion of the transaction, the director now owns 2,538,289 shares in the company, valued at approximately $12,361,467.43. The disclosure for this purchase can be found here. 45.20% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Galectin Therapeutics by 0.4% during the 4th quarter. BlackRock Inc. now owns 604,268 shares of the company’s stock valued at $2,073,000 after acquiring an additional 2,611 shares in the last quarter. MML Investors Services LLC boosted its position in shares of Galectin Therapeutics by 55.8% during the 4th quarter. MML Investors Services LLC now owns 26,926 shares of the company’s stock valued at $92,000 after acquiring an additional 9,642 shares in the last quarter. Stratos Wealth Partners LTD. boosted its position in shares of Galectin Therapeutics by 45.5% during the 4th quarter. Stratos Wealth Partners LTD. now owns 40,950 shares of the company’s stock valued at $140,000 after acquiring an additional 12,796 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Galectin Therapeutics by 7.3% during the 4th quarter. Geode Capital Management LLC now owns 227,175 shares of the company’s stock valued at $779,000 after acquiring an additional 15,410 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Galectin Therapeutics during the 3rd quarter valued at about $107,000. Institutional investors and hedge funds own 12.58% of the company’s stock.
Shares of NASDAQ:GALT traded up $0.30 on Friday, hitting $5.11. 501,365 shares of the company were exchanged, compared to its average volume of 404,262. Galectin Therapeutics has a one year low of $3.10 and a one year high of $9.49. The company has a market cap of $219.10 million, a price-to-earnings ratio of -13.45 and a beta of 3.70.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.
Featured Story: Call Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.